As at now no cure exists for AIDS, but strict adherence to antiretroviral regimens (ARVs) can dramatically slow the disease's progress as well as prevent secondary infections and complications. HIV causes AIDS and interferes with the body's ability to fight infections.
The virus can be transmitted through contact with infected blood, semen or vaginal fluids. However the tide is about to change, There is an ongoing research within Uganda with regards to HIV/AIDS treatment.
Uganda is in the final stages of introducing a new drug that will prevent transmission of HIV/AIDS.
The Cabotegravir injectable drug is an anti-HIV drug that has been cleared by the World Health Organization and has been found to be effective as a pre-exposure treatment.
Now this is a major development in the fight against this deadly and life-threatening virus, with this new found drug HIV/AIDS will be a thing of the past.
Credit: NBS Television
Content created and supplied by: YoungDapper (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More